The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Biocon Biologics collaborates with Malaysia's National Cancer Society to launch a Patient Assistance Program, providing affordable biosimilars like Trastuzumab to underserved cancer patients and ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.